The therapeutic potential for SBT-100 in vivo has been demonstrated here as monotherapy, we have confirmed the efficacy in the form of tumor regression in athymic nude mouse xenograft with TNBC tumors with KRAS(G13D) mutation (at least 50–100 mm3). The gene discussed is KRAS; the disease is neoplasm.